- $77.96m
- $8.61m
- $25.38m
- 10
- 30
- 43
- 16
Annual income statement for Invivyd, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 25.4 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 23.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 65.3 | 227 | 231 | 213 | 202 |
| Operating Profit | -65.3 | -227 | -231 | -213 | -177 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -65.3 | -227 | -241 | -199 | -170 |
| Net Income After Taxes | -65.3 | -227 | -241 | -199 | -170 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -65.3 | -227 | -241 | -199 | -170 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -65.3 | -227 | -241 | -199 | -170 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.232 | -5.15 | -2.19 | -1.77 | -1.43 |
| Dividends per Share |